[ad_1]
Jakarta, CNN Indonesia –
The clinical trial team claims Nusantara vaccine it can create antibodies or immune forces that can last a lifetime. Vaccines for corona virus (Covid-19) is said to form cellular immunity in T lymphocytes.
It is known that the Nusantara vaccine was initiated by the former Minister of Health Terawan Agus Putranto.
“Dr. Terawan’s vaccine has a dendritic character of T cells, which means that an injection is valid for life. So that the financing is more profitable and does not deplete the country’s currencies, because it is produced in the country”, Said a member of When contacted by the Nusantara vaccine clinical trial team, Jajang Edi Prayitno CNNIndonesia.com, Wednesday (2/17).
He explained that the way this vaccine works is built from autologous dendritic cells or components of white blood cells, which are then exposed to the Sars-Cov-2 antigen.
The dendritic cell method is a method that has been used frequently for the treatment of cancer and degenerative diseases until now. He said that in the process of developing this Indonesian vaccine, the clinical trial team was assisted by one of the researchers from AIVITA Biomedical in the United States.
This archipelago vaccine will be specific to individuals. Because technically, each person will have a blood sample taken and then exposed to a dendritic cell vaccine kit. How it works, cells that have recognized the antigen will incubate for 3-7 days.
The result will then be injected back into the body. In the body, these dendritic cells will activate other immune cells to form a memory defense system against Sars Cov-2.
Until now, testing of other vaccines has mainly used inactivated virus, mRNA, recombinant protein methods for adenovirus.
“We are the only ones in the world, in fact, if we succeed in testing the first to the third phase and up to production. That means that we are one of the seven countries in the world that have sovereignty to manufacture vaccines,” he said. explained.
Not only that, Jajang said that the domestic dendritic cell-based vaccine will not experience a decline in function when the virus evolves or mutates. With these findings, Jajang assessed that the Indonesian vaccine can be used whenever an epidemic arises until a new pandemic occurs at a later date.
(khr / bmw)
[ad_2]
